What is the official ID of this bill?

The official print number for this legislation is HR 3093.

When did the legislative process begin?

The process officially started on 2023-05-05.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/hr3093/BILLS-118hr3093ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Who is the primary sponsor?

The primary sponsor is Rep. Hoyle, Val T. [D-OR-4].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Analysis and Potential Impact of HR 3093

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Lowering Drug Prices: New Rules for Taxpayer-Funded Medicines.

Q: What are the main provisions?

Key points include: Drugs and medical services developed with public funds must be sold at reasonable prices. Prices in the U.S. cannot exceed the median prices in Canada and six other high-income countries. Companies must report clinical trial costs and annual revenues from drug sales. Potential price reductions if revenues exceed targets or prices create access barriers.

This bill aims to reduce the cost of prescription drugs and medical services developed with federal research funds. Companies will be required to offer reasonable prices, not exceeding those in other high-income countries, potentially leading to lower healthcare costs for citizens. The act also introduces greater transparency in drug production costs.

Key points

Drugs and medical services developed with public funds must be sold at reasonable prices.

Prices in the U.S. cannot exceed the median prices in Canada and six other high-income countries.

Companies must report clinical trial costs and annual revenues from drug sales.

Potential price reductions if revenues exceed targets or prices create access barriers.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023

Print number: HR 3093

Sponsor: Rep. Hoyle, Val T. [D-OR-4]

Process start date: 2023-05-05

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Lowering Drug Prices: New Rules for Taxpayer-Funded Medicines.

Key Questions about Lowering Drug Prices: New Rules for Taxpayer-Funded Medicines.